The Consortium for the Early Identification of Alzheimer’s Disease

https://www.neurodegenerationresearch.eu/survey/the-consortium-for-the-early-identification-of-alzheimers-disease/

Title of study

The Consortium for the Early Identification of Alzheimer's Disease

Acronym for cohort

CIMA-Q

Name of Principal Investigator - Title

Prof

Name of Principal Investigator - First name

Jean-Paul

Name of Principal Investigator - Last name

Soucy

Address of institution -Institution

McGill University

Address of institution - Street address
Address of institution - City
Address of institution - Postcode
Country

Canada

Website
Contact email

Funding source

CQDM and Brain Canada (with financial support of Health Canada)

Q1a. Please indicate below if your cohort includes or expects to include, incidence of the following conditions?

Alzheimer's disease and other dementias

Q2a. In a single sentence what is the stated aim of the study? (Maximum 30 words)

To advance knowledge about Alzheimer's disease with the mission to develop tools permitting its earliest detection.

Q2b. What distinguishes this case-control study from other studies?

Direct comparison of brain and retinal amyloid content.

Q3a. i) Number of publications that involve use of your cohort to date

0

Q3a. ii) Please give up to three examples of studies to date (PI, Institution, Title of Study)
Q3b. If data on research outputs are already available please paste the publication list/other data or provide a link to where these data are publicly available
Q3c. If no research has been done as yet, please explain in a few sentences what information (i.e. research findings) you expect will be gained from the case-control study

We hope to validate an easy-to-implement retinal scanning technique as an early test for AD detection.

Q4a. Study criteria: what is the age range of participants at recruitment? Age in years From:

55

Q4a. Study criteria: what is the age range of participants at recruitment? To:

85

Q4b. Study criteria: what are the inclusion criteria?
Q4c. Study criteria: what are the exclusion criteria?
Q5a. What is the size of the cohort (i.e. how many participants have enrolled)?

1-1,000

Q5b. What is the expected number of control participants?
Q6a. Please describe what measures are used to characterise participants

Clinical, cognitive, neuroimaging meausures, retinal fluorescence imaging

Q6b. Are there additional measures for participants with the clinical disorder?

No

Q6c. Are there defined primary and secondary endpoints (e.g. defined health parameters)?

If YES please specify
Q7. What is the study design?

Cross sectional survey

Q8. Are your cases matched by

Cogntive function

Q9a. Does your study includes a specialised subset of control participants?
Q9b. If your study includes a specialised subset of control participants please describe
Q10a. Is data collection for this study

Data collection ongoing

Q10b. If data collection is ongoing, are there plans to continue the cohort study beyond the current projected end date?

No

Q11. Are data collected

Only through the study

Q12. Is there a system in place to enable re-contact with patients for future studies?
Q13a. Please give information on data stored in a database (1)

Data summarised in database

% Available

100

Q13a. Please give information on data stored in a database (2)

No

% Available
Q13a. Please give information on data stored in a database (3)

No

% Available
Q13a. Please give information on data stored in a database (4)

No

% Available
Q13a. Please give information on data stored in a database (5)

No

% Available
Please specify language used
% Available

100

Q13b. Please give information on how data is held as individual records

No

% Available
Q14a. Are data available to other groups?
Q14b. If data is available to other groups what is the access policy/mechanisms for access?
Q15. What data sharing policy is specified as a condition of use?
Q16a. Are tissues/samples/DNA available to other groups?
Q16b i) If yes, please describe below
Q16b. ii) In what form are tissues/samples/DNA supplied?
Q16b iii) Is the access policy/mechanism for obtaining samples the same as that for obtaining data (Q14 above)?
Q17. Is information on biological characteristics available to other groups?

Types:
Case Control Studies

Member States:
Canada

Diseases:
Alzheimer's disease & other dementias

Years:
2016

Database Categories:
N/A

Database Tags:
N/A